Manchester-based APIS Assay Technologies acquires New York-based start-up Beogenomics.
11:13 10 September 2020
Manchester-based APIS Assay Technologies has confirmed that it has acquired Beogenomics, a New York-based start-up company.
The specialist software developer works across Bioinformatics and Artificial Intelligence and uses in-house and cloud-based computing resources. It specialises in the development of software tools for genomic data and helping companies construct and run analysis pipelines.
Joachim Schorr, CEO of APIS, said: "We are delighted to announce our acquisition of Beogenomics, which offers strong operational and cultural fits. We look forward to welcoming the talented team and working together to expand our BIOX capacity internally, and build out a new, discrete, and externally-facing service line.
Ian Kavanagh, COO of APIS, said that the move would enable them to "more effectively capture the exciting opportunities presented in the bioinformatics space."